Polypharmacy in Psychiatry Practice, Volume II: Use of Polypharmacy in the "Real World"
Michael S Ritsner
Springer Science & Business Media, Feb 15, 2013 - Medical - 321 pages
Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem. This volume is the first comprehensive, clinically oriented, reference on the multiple medication use to treat psychotic, cognitive, mood and anxiety disorders.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
Polypharmacy in Psychiatry Practice, Volume II: Use of Polypharmacy in the ...
Michael S Ritsner
No preview available - 2013
acid Acta Psychiatr Scand acute add-on adjunctive Affect Disord amisulpride anticholinergic antidepressant antipsy antipsychotic drugs antipsychotic medications antipsychotic monotherapy antipsychotic polypharmacy anxiety disorders aripiprazole associated atypical antipsychotics augmentation of clozapine benzodiazepines Biol Psychiatry bipolar depression bipolar disorder BPRS carbamazepine chotic Clin Psychiatry Clin Psychopharmacol clinical practice clinicians clozapine cognitive comorbid controlled trial Czech DBRCT depressive disorder dosage dose double-blind efficacy evidence fluoxetine guidelines haloperidol hospital improvement increased inositol inpatients lamotrigine lithium long acting antipsychotic major depressive mania Mental Health meta-analysis metabolic syndrome mg/day mirtazapine mood stabilizers negative symptoms Neuropsychopharmacol olanzapine omega-3 PANSS patients with schizophrenia pharmacological placebo prescribed prescription prevalence psychosis psychotic psychotropic drugs quetiapine rates receptor reported risk risperidone Ritsner sample schizoaffective Schizophr Bull schizophrenia schizophrenia patients serotonin side effects significant SSRIs strategies TCAs therapeutic topiramate treated treatment of bipolar treatment of schizophrenia treatment-resistant schizophrenia valproate versus